TITLE

2011 - Review: Antihypertensive treatment prevents cardiovascular events and mortality in cardiovascular disease without hypertension

AUTHOR(S)
Cohn, Jay N.
PUB. DATE
June 2011
SOURCE
ACP Journal Club;6/21/2011, Vol. 154 Issue 6, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a study by Thompson A. M. and colleagues which shows that antihypertensive treatment was helpful in preventing cardiovascular events and mortality in cardiovascular disease without hypertension. The meta-analysis showed that antihypertensive treatment reduced stroke, myocardial infarction (MI) and cardiovascular mortality compared with placebo.
ACCESSION #
65456997

 

Related Articles

  • Can Antihypertensive Treatment Benefit Persons Without Hypertension?  // Neurology Alert;May2011 Supplement, p2 

    The article discusses results of a study which showed that the use of antihypertensive pharmacotherapies may benefit patients at high risk of cardiovascular disease, referencing the report "Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without...

  • Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-analysis. Thompson, Angela M.; Hu, Tian; Eshelbrenner, Carrie L.; Reynolds, Kristi; He, Jiang; Bazzano, Lydia A. // JAMA: Journal of the American Medical Association;3/2/2011, Vol. 305 Issue 9, p913 

    This article discusses a study which examined the effect of antihypertensive treatment on secondary prevention of cardiovascular disease (CVD) events and all-cause mortality among persons without clinically defined hypertension. A standardized protocol was utilized to extract information on...

  • Treatment of High-Risk Hypertensive Patients. Ruilope, Luis M.; Segura, Julian; Tocci, Giuliano; Volpe, Massimo // High Blood Pressure & Cardiovascular Prevention;Feb2006, Vol. 13 Issue 1, p13 

    Cardiovascular disease represents the leading cause of morbidity and mortality in Western countries, and hypertension-related cardiovascular events affect about 37 million people per year, worldwide. In this perspective, hypertension represents a reference paradigm to illustrate strategies aimed...

  • 2011 - Review: Antihypertensive treatment prevents cardiovascular events and mortality in cardiovascular disease without hypertension. Cohn, Jay N. // ACP Journal Club;6/21/2011, Vol. 154 Issue 6, p5 

    Question In patients with a history of cardiovascular disease (CVD) who do not have hypertension, does antihypertensive treatment reduce risk for CVD events and mortality? Review scope Included studies compared antihypertensive treatment with placebo in adults >18 years of age, who had CVD or...

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 2. Assessing and reducing global atherosclerotic risk among hypertensive patients. Hemmelgarn, Brenda R.; Grover, Steven; Feldman, Ross D. // CMAJ: Canadian Medical Association Journal;9/13/2005, Vol. 173 Issue 6, p593 

    Discusses the strategies for assessing and reducing atherosclerotic risk among hypertensive patients. Connection between hypertension and cardiovascular disease; Effect of antihypertensive treatment on the risk of coronary artery disease and cerebrovascular events; Methods to calculate the...

  • Are new antihypertensive agents better than old antihypertensive agents in preventing cardiovascular complications? Dickerson, Lori M.; Carek, Peter J. // Journal of Family Practice;Jan2002, Vol. 51 Issue 1, p9 

    This paper discusses research being done on antihypertensive agents. It references a study by J. A. Stessen, J. G. Wang and L. Thijs published in the 2001 issue of "Lancet." This meta-analysis compares the efficacy of older antihypertensive agents with new antihypertensive agents in preventing...

  • Pravastatin was not better than usual care in reducing all cause mortality or CHD events. Probstfield, J. L.; Davis, B. R. // Evidence Based Medicine;Jul2003, p106 

    The article presents a study that explores on the efficacy of pravastatin in reducing mortality or cardiovascular heart diseases (CHD) events in elderly patients with moderate elevation of low density lipoprotein cholesterol (LDL-C) and hypertension in Canada, the U.S., U.S. Virgin Islands and...

  • Cardiovascular Risk in Hypertensive Patients with Renal Dysfunction. Ravera, Maura; Re, Michela; Weiss, Ursula; Cannavo, Rossella; Deferrari, Luca; Deferrari, Giacomo // High Blood Pressure & Cardiovascular Prevention;Mar2009, Vol. 16 Issue 1, p13 

    Chronic kidney disease (CKD) is associated with elevated cardiovascular morbidity and mortality. Cardiovascular disease (CVD) is highly prevalent in CKD and mortality due to CVD is 5- to 200-fold higher in dialysis patients than in the general population. The increase in CVD burden in patients...

  • Cardiovascular Risk in Hypertensive Patients with Renal Dysfunction. Ravera, Maura; Re, Michela; Weiss, Ursula; Cannavo', Rossella; Deferrari, Luca; Deferrari, Giacomo // High Blood Pressure & Cardiovascular Prevention;Dec2009, Vol. 16 Issue 4, p13 

    Chronic kidney disease (CKD) is associated with elevated cardiovascular morbidity and mortality. Cardiovascular disease (CVD) is highly prevalent in CKD and mortality due to CVD is 5- to 200-fold higher in dialysis patients than in the general population. The increase in CVD burden in patients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics